Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Gregory B. Sephton, Partner, Pierce Bainbridge Beck Price & Hecht LLP to speak at TKG's EventFor further details, please visit: https://www.theknowledgegroup.org/ About Gregory B. Sephton, Ph.D. Gregory B. Sephton, Ph.D., has over 25 years of experience in all aspects of patent litigation and has played leading roles in litigating and trying patent cases for a number of technology leaders, including Emory University, AstraZeneca, Novartis, Sanofi and Warner Chilcott. Most recently, Gregory led Forward Pharma to a $1.25 billion settlement in its worldwide patent dispute with Biogen over rights to its Tecfidera® multiple sclerosis treatment. His litigation experience spans diverse technologies involving medical devices, chemicals, pharmaceuticals and biologicals. Greg also advises clients on patent strategy, as well as ex parte and inter partes patent reexaminations. He has particular experience litigating billion dollar pharmaceutical patent cases under the Hatch-Waxman Act, including involving anti-viral drugs, insomnia drugs, drugs for Alzheimer's disease, anti-fungal drugs, anti-bacterial drugs and treatments, and anti-ulcer drugs, as well as a wide array of drug formulation technologies. He also has significant experience in intellectual property counseling, due diligence and transactions. Prior to joining Pierce Bainbridge, Gregory was a partner at Kramer Levin Naftalis & Frankel LLP. Before that, he spent over 20 years at the Chambers Band 1-ranked New York IP boutique, Fitzpatrick, Cella, Harper & Scinto, where he was also a partner. Gregory holds degrees from the University of Toronto (B.Sc. Hons), Brandeis University (Ph.D., biochemistry, under a Merck grant) and Suffolk University (J.D.). About Pierce Bainbridge Beck Price & Hecht LLP Pierce Bainbridge is a top-tier litigation firm that is changing the way companies and individuals approach major disputes. We are relentless, creative, and aggressive, and we're always on the hunt for strategic and tactical advantages that can benefit our clients and secure victory. Our team is composed of the finest trial lawyers from the best law schools who were trained at the biggest law firms in the world. We know how to win – and that's what we do best. Attorneys at our firm have won jury verdicts and settlements totaling well over $3 billion dollars. We provide our clients with a high-stakes litigation force to vindicate and protect their rights. We approach every case with unparalleled dedication, precision, and creativity. We learn our clients' business, understand their disputes, analyze our opponents, and do everything it takes to obtain the best outcome possible. We know that litigation can be expensive, so we strive to handle cases in an extraordinarily efficient manner without compromising the outstanding quality of our work. Unlike our competitors, we're always willing and able to devise creative and unorthodox fee arrangements that take account of the business needs of each of our clients. CAP is a leading independent consulting firm specializing in executive and director compensation and related corporate governance matters. Our consultants have served as independent adviser to Boards and senior management at many leading companies in the areas of compensation strategy, program design and in promoting sound corporate governance principles. Event Synopsis: Filing a Paragraph IV (PIV) patent challenge remains to be one of generic drug manufacturers' strategies to gain entry into the market before the patents' expiration. Although pursuing a challenge presents significant business opportunities, it poses additional complexities. In the context of medical diagnostics and methods of treatment claims, these challenges include divided infringement and Section 101 problems. Counsel to both brand and generic companies should be prepared with the emergence of new developments that will shape the Paragraph IV litigation landscape, particularly claims directed to diagnostics and methods of treatment. Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of pursuing or defending against a paragraph IV challenge and as they delve into an in-depth analysis of the current trends and recent filings. Speakers will also provide the audience with the best litigation practices and practical strategies to help their clients cope with the evolving legal climate. Key topics include: • Section 101 Patentability Challenges - Recent Developments for Method of Treatment Patent Claims • Courts' Application of the Mayo Two-Part Test • Divided Infringement in Medical Diagnostics and Methods of Treatment Claims • The Akamai test • Best Litigation Practices and Practical Tips About The Knowledge Group/The Knowledge Congress Live Webcast Series The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/ End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number